Layer, Chiang, et al. Genome Biology
As Alnylam Files to Begin Testing Cholesterol Drug in Humans, Questions Linger Over Delivery Tech
Alnylam said that the drug candidate is the first to incorporate the company's second-generation lipid nanoparticle technology. However, Alnylam is currently embroiled in a lawsuit with partner Tekmira Pharmaceuticals over ownership of that very delivery technology.
New to GenomeWeb? Register here quickly.